MediciNova Inc MNOV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.31
- Day Range
- $1.28–1.36
- 52-Week Range
- $1.17–1.96
- Bid/Ask
- $0.63 / $1.44
- Shares Outstanding
- 49.22M
- Market Cap
- $65.96M
- Volume/Avg
- 17,384 / 38,263
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 101.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6
- Website
- https://www.medicinova.com
Valuation
|
Metric
|
MNOV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.54 |
Price/Sales | 101.23 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MNOV
|
|---|---|
Quick Ratio | 8.91 |
Current Ratio | 9.09 |
Interest Coverage | — |
Quick Ratio
MNOV
Profitability
|
Metric
|
MNOV
|
|---|---|
Return on Assets (Normalized) | −22.61% |
Return on Equity (Normalized) | −24.28% |
Return on Invested Capital (Normalized) | −26.91% |
Return on Assets
MNOV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Nthbm | — | |||
| Athersys Inc
ATHXQ
| — | Tvr | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sksmtxs | Nnnzsg | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pbpkqdsg | Ggkkrx | $64B | |||
| UCB SA
UCBJF
| — | Bmyt | $61B | |||
| UCB SA ADR
UCBJY
| — | Ttz | $61B | |||
| argenx SE
ARGNF
| — | Mwnm | $56B | |||
| argenx SE ADR
ARGX
| Mvmmrlwgh | Khcc | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zcwxqdk | Qltpp | $38B | |||
| CSL Ltd
CMXHF
| — | Rgrjml | $36B |
United States